What is Biotia?
Biotia operates within the critical sector of infectious disease diagnostics, leveraging advanced genomics and artificial intelligence to develop cutting-edge solutions. Their product portfolio, including BIOTIA-DX for precise microorganism identification and the BIOTIA-ID line for common infections like urinary and joint issues, serves a diverse clientele encompassing researchers, clinicians, and patients. By integrating modern sequencing technology and collaborating with esteemed institutions such as the Mayo Clinic and the Rockefeller Foundation, Biotia aims to significantly enhance global health monitoring and bolster the response to emerging infectious disease threats.
How much funding has Biotia raised?
Biotia has raised a total of $10.6M across 3 funding rounds:
Angel/Seed
$2.4M
Debt
$155K
Series A
$8M
Angel/Seed (2019): $2.4M with participation from Hyperplane Venture Capital and Falcon III Ventures
Debt (2021): $155K led by PPP
Series A (2022): $8M, investors not publicly disclosed
Key Investors in Biotia
Hyperplane Venture Capital
Hyperplane Venture Capital is a seed-stage firm based in Boston, Massachusetts, known for investing in companies that leverage machine intelligence, sensor technology, and cloud computing across various sectors including digital health.
Falcon III Ventures
Falcon III Ventures is an investment entity that has participated in Biotia's funding rounds. Further details on their investment focus are not specified.
What's next for Biotia?
The recent major strategic investment, alongside the overall enterprise-level funding Biotia has garnered, positions the company for accelerated scaling and market penetration. This capital infusion is expected to fuel further research and development, expand commercialization efforts, and potentially broaden the company's technological applications in diagnostics. With a foundation built on scientific rigor and strategic partnerships, Biotia is poised to solidify its leadership in the genomics-driven diagnostics market, addressing urgent global health challenges.
See full Biotia company page
